Regenxbio to present interim update of RGX-314 Phase I/IIA trial
Category: #health  By Pankaj Singh  Date: 2019-08-29
  • share
  • Twitter
  • Facebook
  • LinkedIn

Regenxbio to present interim update of RGX-314 Phase I/IIA trial
  • Dr. Jeffery Heier, the primary investigator of the trial, will present the data during the Retina Subspecialty day program held at AAO (American Academy of Ophthalmology) 2019 annual meeting, CA
     
  • The biotechnology firm is also planning to initiate a Phase 2b trial for wet AMD by the end of 2019

Regenxbio Inc., a U.S.-based leading clinical-stage biotechnology company has recently announced that an interim trial update from the Phase I/IIa clinical trial of RGX-314 which is targeted for treating wet AMD (age-related macular degeneration) will be reported at the American Academy of Ophthalmology (AAO) annual meeting in California, during a presentation at the Retina Subspecialty Day program.

As per sources close to the matter, Dr. Jeffery Heier, Director and Co-President of Retina Research at Ophthalmic Consultants & primary investigator of the trial, will present the interim results that include data for all 5 dose cohorts. 

According to Steve Pakola, M.D., Senior V.P. & CMO of Regenxbio, the company is elated by the previously announced positive interim data from the Phase I/IIa trial along with the potential of proprietary NAV® gene therapy as a one-time treatment for wet age-related macular degeneration.

He added that the company is looking forward to demonstrating data from all 5 dose cohorts from the clinical pilot in wet AMD at the coming American Academy of Ophthalmology meeting.

For the record, Regenxbio is a leading bio-technology company focused on improving lives through the potential of gene therapy. The firm’s NAV technology platform is a proprietary AAV (adeno-associated virus) gene delivery platform and consists of exclusive rights to more than 100 novel adeno-associated virus vectors, including AAVrh10, AAV9, AAV8 and AAV7.

Regenxbio and its third-party NAV technology platform licensees are also using NAV for the development of a wide pipeline of candidates in several therapeutic areas.

Source Credit: https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-present-interim-phase-iiia-trial-update-rgx-314



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Early data from first human CRISPR trials reveals promising results
Early data from first human CRISPR trials reveals promising results
By Pankaj Singh

Vertex Pharmaceuticals and CRISPR Therapeutics have recently revealed early data from their joint trials to test CRISPR treatment in humans. The data was obtained from two patients suffering from serious blood disorder...

Novartis’ trial of Entresto reveals potential beyond HFrEF treatment
Novartis’ trial of Entresto reveals potential beyond HFrEF treatment
By Pankaj Singh

Swiss pharma-company Novartis has reportedly revealed subgroup results from its global PARAGON-HF Phase III study. The trial involved a study of patients suffering from HFpEF (heart failure with preserved ejection frac...

Nike to halt direct sale of its shoes and clothes through Amazon
Nike to halt direct sale of its shoes and clothes through Amazon
By Pankaj Singh

In efforts to retain their relevance in the continuously evolving world of ecommerce, companies are losing the personal touch they once had with their customers. Lately however, prominent brands that have a well-establ...